# These authors have equally contributed to the work S2 General Considerations NMR spectra were recorded on a Bruker AV-III-500 MHz NMR spectrometer. Chemical shifts are reported in δ values in ppm downfield from TMS as the internal standard. 1 H data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet), coupling constant (Hz), integration. 13 C chemical shifts are reported in δ values in ppm downfield from TMS as the internal standard. High resolution mass spectra were recorded on a Waters LCT Premier system. Low resolution mass spectra were obtained on Waters Acquity Ultra Performance LC with electrospray ionization and SQ detector. Analytical HPLC was performed on a Waters Autopurification system with PDA, MicroMass ZQ and ELSD detector. Analytical thin layer chromatography was performed on 250 μM silica gel F 254 plates. Preparative thin layer chromatography was performed on 1000 μM silica gel F 254 plates. Flash column chromatography was performed employing 230-400 mesh silica gel. Solvents were HPLC grade. All reagents were purchased from either Aldrich or Acros Organics and used without purification. All reactions were performed under argon protection. The synthesis of 1-4 and 11 is reported elsewhere. 1
. Synthesis of YK5-biotin2 (5). Reagents and conditions: a. potassium phthalimide, DMF, 110 °C,18 h, 84%; b. tosyl chloride, Et 3 N, DMAP, CH 2 Cl 2 , 5 °C to rt, 24 h, 87%; c. 1-Boc-piperazine, K 2 CO 3 , dioxane, 80 °C, 22 h, 72%; d. TFA:CH 2 Cl 2 (1:4), rt, 1 h; e. N,N'- (2-((2-fluoro-4,6-dimethoxypyrimidin-5yl) thio)pyrimidine-4,6-diyl)diacetamide (11), K 2 CO 3 , DMF, 90 °C, 1.5 h, 65%; f. NH 2 NH 2 , MeOH, rt, 2 h then 1M NaOH (aq.), 50 °C, 1.5 h, 93%; g. D-biotin, EDCI, DMAP, CH 2 Cl 2 , sonicate, 2 h, 55%; h. acryloyl chloride, Et 3 N, CH 2 Cl 2 , 0 °C, 37%. (2-(2-(2-(2-Hydroxyethoxy) ethoxy)ethoxy)ethyl)isoindoline-1,3-dione (8). 2 7 (1.22 g, 3.5 mmol) and potassium phthalimide (0.713 g, 3.85 mmol) were suspended in anhydrous DMF (10 mL) and heated at 110 °C for 18 h. The reaction mixture was concentrated under reduced pressure and the residue was dissolved in CH 2 Cl 2 (50 mL) and washed with 1M HCl (2 x 20 mL), brine (2 x 20 mL), dried over MgSO 4 , and filtered. Solvent was removed under reduced pressure to give an oil which was purified by column chromatography (EtOAc) to afford 0.95 g (84%) of 8. 1 H NMR (500 MHz, CDCl 3 ): δ 7.85 (dd, J = 3.1, 5.4 Hz, 2H), 7.72 (dd, J = 3.0, 5.5 Hz, 2H), 3.91 (t, J = 5.9 Hz, 2H), 3.75 (t, J = 5.8 Hz, 2H), 3.55-3.73 (m, 12H); MS (m/z): [M+Na] + 346.1.
2-

2-(2-(2-(2-(1,3-Dioxoisoindolin-2-yl)ethoxy)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (9).(2)
A solution of 8 (0.95 g, 2.7 mmol), Et 3 N (395 µL, 0.287 g, 2.8 mmol) and DMAP (33 mg, 0.27 mmol) in CH 2 Cl 2 (30 mL) was cooled to 5°C with ice-bath. p-Toluenesulfonyl chloride (0.515 g, 2.7 mmol) was added in portions at 5 °C and after 30 minutes the ice-bath was removed and stirring continued at rt for 24 h. The reaction mixture was added to a seperatory funnel and washed with 1N HCl (2 x 25 mL), water (25 mL), and brine (2 x 25 mL). The organic layer was dried over MgSO 4 , filtered and concentrated to give an oil which was purified by column chromatography (hexane:EtOAc, 6:4 to 4:6) to give 1.12 g (87%) of 9. 1 
tert-Butyl 4-(2-(2-(2-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)ethoxy)ethoxy)ethyl)piperazine-1carboxylate (10).
To a solution of 9 (1.10 g, 0.0023 mol) in dioxane (25 mL) was added 1-Bocpiperazine (1.07 g, 0.0058 mol) and K 2 CO 3 (1.37 g, 0.0099 mol) and heated at 80 °C for 22 h. Solvent was removed under reduced pressure and the residue was taken up into CH 2 Cl 2 (100 mL) and washed with water (2 x 50 mL) and brine (2 x 50 mL). The organic layer was dried over MgSO 4 , filtered and concentrated to an oil which was purified by column chromatography (CH 2 Cl 2 :MeOH-NH 3 (7N), 1:0 to 30:1) to give 0.819 g (72%) of 10. 1 To 10 (542 mg, 1.10 mmol) in CH 2 Cl 2 (28 mL) was added TFA (7 mL) dropwise and stirred at rt for 1 h. The reaction mixture was concentrated under reduced pressure and TFA removed by coevaporating with MeOH several times and drying under high vacuum overnight. To this was added K 2 CO 3 (381 mg, 2.76 mmol) and DMF (20 mL) and the resulting suspension was stirred at rt for 10 min. Then 11 (421 mg, 1.1 mmol) was added and the mixture was heated at 90 °C for 90 min. The solvent was removed under reduced pressure and the residue was purified by column chromatography (CH 2 Cl 2 :MeOH, 100:1 to 25:1) to give 0.537 g (65%) of 12. 1 To 15 mg (0.020 mmol) of 14 in 2 ml of CH 2 Cl 2 at 0 °C was added 83 μl (60 mg, 0.6 mmol) of Et 3 N. Then 3.3 μl (3.6 mg, 0.04 mmol) of acryloyl chloride in CH 2 Cl 2 (0.5 mL) was added dropwise at 0°C. After 1 h, an additional 3.3 μl of acryloyl chloride in CH 2 Cl 2 (0.5 mL) was added dropwise. This was repeated four more times at 30 min. intervals for a total reaction time of 3.5 hours (total acryloyl chloride, 19.8 μl, 21.6 mg, 0.24 mmol). The reaction mixture was concentrated under reduced pressure and the residue purified by preparatory TLC (CH 2 Cl 2 :MeOH-NH 3 (7N), 10:1) to yield 6.0 mg (37%) of 5. 1 4-(4-(1,3-dioxoisoindolin-2-yl) butyl)piperazine-1-carboxylate (16). N-(4bromobutyl)phthalimide (15; 1.95 g, 6.89 mmol) and sodium iodide (81 mg, 0.537 mmol) were added to a suspension of K 2 CO 3 (1.64 g, 11.88 mmol) and 1-Boc-piperazine (1.00 g, 5.37 mmol) in acetone (25 mL) and refluxed for 22 h. The reaction mixture was filtered and the solid was washed with acetone (3 x 50 mL). The filtrate was concentrated and the residue purified by column chromatography (hexane:EtOAc, 7:3 to 0:1) to afford 2.08 g (100%) of 16. 1 (2-(4-(4-(1,3-dioxoisoindolin-2-yl) butyl)piperazin-1-yl)-4,6-dimethoxypyrimidin-5ylthio)pyrimidine-4,6-diyl)diacetamide (17). To 16 (429.7 mg, 1.11 mmol) in CH 2 Cl 2 (12 mL) was added TFA (3 mL) dropwise and stirred at rt for 1 h. The reaction mixture was concentrated under reduced pressure and TFA removed by co-evaporating with MeOH several times and drying under high vacuum overnight. To this was added K 2 CO 3 (384 mg, 2.78 mmol) and DMF (21 mL) and the resulting suspension was stirred at rt for 10 min. Then 11 (424 mg, 1.11 mmol) was added and the suspension was heated at 90 °C for 90 min. Solvent was removed under reduced pressure and the residue was purified by column chromatography (CH 2 Cl 2 :MeOH, 100:1 to 40:1) to give 0.355 g (49%) of 17. 1 (4-(4-aminobutyl) piperazin-1-yl)-4,6-dimethoxypyrimidin-5-ylthio)pyrimidine-4,6diamine (18). 17 (0.355 g, 0.546 mmol) in MeOH (10 mL) was added hydrazine hydrate (797 µL, 0.820 g, 16.4 mmol) and stirred at rt for 2 h. Then 5 mL of 1M NaOH was added and the reaction mixture was heated at 55°C for 2 h. The reaction mixture was concentrated under reduced pressure and the residue purified by column chromatography (CH 2 Cl 2 :MeOH-NH 3 (7N), 20:1 to 5:1) to give 0.228 g (96%) of 18. 1 4-(4-(5-(4,6-diaminopyrimidin-2-ylthio)-4,6-dimethoxypyrimidin-2-yl) tert-butyl 4-(4-(5-(4-acrylamido-6-aminopyrimidin-2-ylthio)-4,6-dimethoxypyrimidin-2yl)piperazin-1-yl)butylcarbamate (20). To 80 mg (0.149 mmol) of 19 in 8 ml of CH 2 Cl 2 at 0 °C was added 414 μl (298 mg, 2.98 mmol) of Et 3 N. Then 14.5 μl (16.2 mg, 0.179 mmol) of acryloyl chloride was added. After 30 min. an additional 14.5 μl of acryloyl chloride was added at 0 °C. This was repeated two more times for a total reaction time of 2 hours (total acryloyl chloride, 58 μl, 64.8 mg, 0.716 mmol). The reaction was quenched by the addition of 1 mL MeOH and then concentrated under reduced pressure. The residue was purified by preparatory TLC (CH 2 Cl 2 :MeOH-NH 3 (7N), 15:1) to yield 42.5 mg (48%) of 20. 1 
tert-Butyl
2-(2-
tert-butyl
YK5-beads (6).
A solution of 20 (45 mg, 0.076 mmol) in 3 ml of CH 2 Cl 2 was added 0.75 mL of TFA dropwise at rt. After stirring for 45 min., the reaction mixture was concentrated under reduced pressure. TFA was removed by co-evaporating with MeOH several times and drying
